苯妥英对急性视神经炎视网膜神经节细胞-内丛状层的影响:II期随机试验分析
结果显示,6个月时苯妥英组黄斑区神经节细胞-内丛状层厚度较安慰剂组厚6.79 μm(p=0.006),且该指标较视盘周围视网膜神经纤维层更敏感。
要点
- 苯妥英治疗6个月时黄斑区神经节细胞-内丛状层厚度显著厚于安慰剂组。
- 黄斑区神经节细胞-内丛状层厚度与视觉诱发电位潜伏期和波幅相关。
- 黄斑区神经节细胞-内丛状层作为神经保护标志物优于视盘周围视网膜神经纤维层。
核心结论
- 苯妥英与急性视神经炎患者6个月时黄斑区神经节细胞-内丛状层厚度更好的保留相关。
- 黄斑区神经节细胞-内丛状层作为神经保护标志物优于视盘周围视网膜神经纤维层。
研究设计与样本
- 研究为苯妥英治疗急性视神经炎II期随机、安慰剂对照、双盲试验的二次分析。
- 使用Spectralis光学相干断层扫描提取基线和6个月时黄斑区神经节细胞-内丛状层厚度。
主要发现
- 6个月时苯妥英组患眼黄斑区神经节细胞-内丛状层厚度较安慰剂组厚6.79 μm(p=0.006,SE=2.35 μm)。
- 苯妥英组和安慰剂组黄斑区神经节细胞-内丛状层厚度估计均值分别为73.8 μm(SE=2.40 μm)和67.0 μm(SE=2.2 μm)。
- 6个月时较高的黄斑区神经节细胞-内丛状层厚度与较低的视觉诱发电位潜伏期(p<0.0001)和较高的波幅(p=0.013)相关。
- 黄斑区神经节细胞-内丛状层的神经保护效应较视盘周围视网膜神经纤维层更稳健。
临床怎么用
- 对于急性视神经炎患者,可考虑使用苯妥英以减缓神经轴索损失,但需结合个体情况。
- 黄斑区神经节细胞-内丛状层可作为评估神经保护治疗效果的敏感影像学标志物。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Acute demyelinating optic neuritis (AON) can lead to irreversible neuroaxonal loss. We investigated the neuroprotective effects of phenytoin on macular ganglion cell-inner plexiform layer (mGCIPL) thickness. METHODS: We reanalyzed Spectralis optical coherence tomography scans from the phenytoin AON trial (NCT01451593), a randomized, placebo-controlled, double-blind phase 2 trial. Participants attended 2 trial centers in London or Sheffield, United Kingdom. Patients with unilateral AON, age 18-60 years, within 2 weeks of onset, with visual acuities 6/9 or worse, were randomly assigned (1:1) to oral phenytoin (4-6 mg/kg/d) or placebo for 3 months, stratified by onset time, center, previous multiple sclerosis diagnosis, disease-modifying treatment, and corticosteroid use. Macular ganglion cell-inner plexiform layer thicknesses were extracted at baseline and 6 months. Linear regression models evaluated treatment effects on 6-month affected eye mGCIPL, adjusting for 6-month full-field visual evoked potential (VEP) latency and amplitude and baseline variables including mGCIPL thicknesses, steroid use, baseline acuity, and time interval to treatment. We also compared neuroprotective effects between peripapillary retinal nerve fiber layer (pRNFL) and mGCIPL outcomes. RESULTS: Eighty patients (39 phenytoin: 41 placebo) with a mean age of 33.59 years, 70% female, participated in this study. At 6 months, significant treatment effects were estimated for phenytoin vs placebo (affected eye mGCIPL thicker by 6.79 μm, p = 0.006, [SE = 2.35 µm]); estimated means for mGCIPL thickness for phenytoin vs placebo were 73.8 μm (SE = 2.40 μm) and 67.0 μm (SE = 2.2 μm), respectively. Treatment effects appeared to be greater for worse baseline acuities. At 6 months, higher mGCIPL thicknesses were associated with lower VEP latencies (p < 0.0001) and higher VEP amplitudes (p = 0.013). Neuroprotective effects on mGCIPL outcomes were more robust than for pRNFL outcomes. DISCUSSION: This study supports superiority of the mGCIPL over the pRNFL as a neuroprotective marker after AON and demonstrates strong associations with myelination, providing additional mechanistic insights. TRIAL REGISTRATION INFORMATION: This trial is registered with ClinicalTrials.gov, number NCT01451593; submitted for registration on October 11, 2011; first patient enrollment was on February 2, 2012. CLASSIFICATION OF EVIDENCE: This study provides Class II evidence that compared with placebo, phenytoin is associated with greater preservation of the mGCIPL thickness in patients with acute demyelinating optic neuropathy.
引用
- Kodali S, Bianchi A, Raftopoulos R, et al. Effects of Phenytoin on the Retinal Ganglion Cell-Inner Plexiform Layer in Acute Optic Neuritis: Analysis of a Phase II Randomized Trial. Neurology. 2025. PMID: 40997284. doi:10.1212/WNL.0000000000213951
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。